Item 2 - Properties
−Removed: We have eight manufacturing facilities with two located in Indiana, two in Mexico, and one located in each of Poland, Romania, China, and Thailand.
−Removed: These facilities occupy approximately 1,499,000 square feet in aggregate, substantially all of which are owned.
+Added: We have eleven manufacturing facilities, ten of which are owned and one (in Indiana) is leased, with three located in Indiana (two of which are fully operational), two in Mexico, and one located in each of Poland, Romania, The Netherlands, India, China, and Thailand.
+Added: These facilities occupy approximately 2,057,000 square feet in aggregate.
+Added: The Netherlands and India manufacturing facilities were acquired on July 1, 2026, see Note 22 - Subsequent Event of Notes to Consolidated Financial Statements for more information.
We lease a facility in the Netherlands to accommodate our support services there.
In addition, we own a 42,000 square-foot building to house our headquarters located in Jasper, Indiana.
−Removed: Additionally, we executed a lease for a third manufacturing facility in Indiana to expand our medical CMO footprint and production has not started.
−Removed: This lease adds 308,000 square feet.
−Removed: When the leased facility is fully operational, it will replace the existing Indianapolis, Indiana facility.
−Removed: Our Tampa facility, excluded from above, is classified as held for sale, see Note 4 - Restructuring Activities of Notes to Consolidated Financial Statements for more information.
+Added: Our Tampa facility, excluded from above, was sold during fiscal year 2026, see Note 4 - Restructuring Activities of Notes to Consolidated Financial Statements for more information.
Generally, our manufacturing facilities are utilized at normal capacity levels on a multiple shift basis.
1 unchanged sentence
We continually assess our capacity needs and evaluate our operations to optimize our service levels by geographic region.
+Added: We executed a lease in fiscal year 2025 for a third manufacturing facility in Indiana to expand our medical CDMO footprint and production has not started.
+Added: When the leased facility is fully operational, it will replace the existing Indianapolis, Indiana facility.
See Item 1A - Risk Factors for information regarding financial and operational risks related to our international operations.
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.